No Big Blockbuster Bailouts Act
In committee: it can still change before the session ends.
- Stage
- In committee
- Started in
- Senate
- Sponsors
- 3
- Latest action
- Oct 21, 2025
What it does
The No Big Blockbuster Bailouts Act would amend the Social Security Act to increase the price threshold for orphan drugs under the Medicare Drug Price Negotiation Program from $200 million to $400 million in annual U.S. sales, making it less likely that such drugs would be subject to federal price negotiations. The change applies specifically to drugs designated for rare diseases with no other approved indications, as defined by the Federal Food, Drug, and Cosmetic Act. The amendment would take effect for initial price applicability years beginning on or after January 1, 2028. This bill affects pharmaceutical manufacturers of orphan drugs and could influence Medicare spending on high-cost…
No official summary is available here. This one was written by AI from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
In the news
Reporting that may mention this subject. Possible matches are labeled.
Loading coverage…
Where it goes next
While a bill can still move, the questions are about people and money.